{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001719406","name":"NRX Pharmaceuticals, Inc.","summary":"NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. Its lead candidates are KETAFREE (preservative-free generic ketamine), NRX-100 (IV ketamine formulation), and NRX-101 (oral fixed-dose D-cycloserine/lurasidone combination). Through majority-owned subsidiary HOPE Therapeutics, Inc., the company operates interventional psychiatry clinics in Florida offering ketamine infusion, TMS, Spravato, hyperbaric therapy, and digital therapeutics.","people":[],"products":[{"name":"KETAFREE","type":"platform","description":"Abbreviated New Drug Application-stage preservative-free generic ketamine formulation for IV infusion; ANDA filed with priority review requested in September 2025."},{"name":"NRX-100","type":"platform","description":"Preservative-free IV ketamine NDA candidate for treatment of suicidal ideation in depression including bipolar depression; Fast Track Designation granted."},{"name":"NRX-101","type":"platform","description":"Oral fixed-dose combination of D-cycloserine and lurasidone for bipolar depression with suicidal ideation; holds FDA Breakthrough Therapy Designation."},{"name":"HOPE Therapeutics Network","type":"service","description":"Interventional psychiatry clinics in Florida offering ketamine infusion, TMS, Spravato, stellate ganglion blocks, hyperbaric therapy, and digital therapeutics."}],"partnerships":[{"partner_name":"Osmind, Inc.","partnership_type":"development","description":"Contracted to analyze and submit Real World Evidence from 65,000 IV ketamine patients and 6,000 intranasal S-ketamine patients for NRX-100 NDA support.","start_date":null},{"partner_name":"Nephron Pharmaceuticals, Inc.","partnership_type":"strategic","description":"Contract manufacturer for KETAFREE registration lots; completed manufacturing readiness audit with no deficiencies identified.","start_date":null},{"partner_name":"neurocare AG","partnership_type":"strategic","description":"Clinical collaboration and collaboration on NRX-101 as therapy to enhance effectiveness of TMS; partnership initiated during 2025.","start_date":null},{"partner_name":"EMOBOT, Inc.","partnership_type":"strategic","description":"Partnership to deploy continuous patient monitoring of depression, PTSD, and suicidality across HOPE clinical footprint for accountable care initiatives.","start_date":null},{"partner_name":"B-Group (Dallas, TX)","partnership_type":"strategic","description":"Provided funding to support development of HOPE Therapeutics operating model and initial clinic acquisitions during 2025.","start_date":null},{"partner_name":"Ampa Health","partnership_type":"strategic","description":"HOPE completed clinical training on Ampa Health TMS device and initiated the ONE-D protocol at Florida locations in November 2025.","start_date":null}],"affiliations":[],"origin":{"leaf":"a648bd8af87f16f5715e61638d3160e84428b35782ea38fa1229888c9f8e5d96","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"3ecbf1e19bfcbf1784d250830b66a2ec04e2dee1d5358451c2c30f350ecdb1a6","parent":"785938d631a9ef312b0ab3e74b78a5d6db5e3e92cdf94056643565b4acd541d5","source":"0001437749-26-009418","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":98,"hourly_limit":500,"remaining":402,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}